Low Complication Rates With Totally Implantable Access Port Use in Epoprostenol Treatment of Pulmonary Hypertension

Journal of Heart and Lung Transplantation

Volumn 28, Issue 3, 2009, Pages 273-279

  Dickinson, Michael G ^a   Schölvinck, Elisabeth H ^a   Boonstra, Anco ^b   Vonk Noordegraaf, Anton ^b   Snijder, Repke J ^c   Berger, Rolf M F ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BLOODSTREAM INFECTION; CAUSE OF DEATH; CHILD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IMPLANTABLE PORT SYSTEM; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK FACTOR; SCHOOL CHILD; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CATHETERS, INDWELLING; CHILD; CHILD, PRESCHOOL; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 61749084532     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2008.11.913     Document Type: Article

References (24)

1. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107 (1987) 216-223
2. Gaine S., and Rubin L. Primary pulmonary hypertension. Lancet 352 (1998) 719-725
3. Cheever K.H. An overview of pulmonary arterial hypertension. J Cardiovasc Nurs 2 (2005) 108-116
4. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
5. Cremona G., and Higenbottam T. Role of prostacyclin in the treatment of primary pulmonary hypertension. Am J Cardiol 75 (1995) 67A-71A
6. Cabrol S., Souza R., Jais X., et al. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 26 (2007) 357-362
7. Sitbon O., Humbert M., and Simonneau G. Primary pulmonary hypertension: current therapy. Progr Cardiovasc Dis 45 (2002) 115-128
8. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334 (1996) 296-302
9. McLaughlin V.V., Genthner D.E., Panella M., et al. Reduction in pulmonary vascular resistance with long term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338 (1998) 273-277
10. McLaughlin V.V., Shillington A., and Rich S. Survival in primary pulmonary hypertension. The impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
11. Humbert M., Sanchez O., Fartoukh M., et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 13 (1999) 1351-1356
12. Rosenzweig E.B., Kerstein D., and Barst R. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99 (1999) 1858-1865
13. Oudiz R.J., Allison W., Beckmann X.J., et al. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. Chest 126 (2004) 90-94
14. Centers for Disease Control and Prevention (CDC). Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension-seven sites, United States, 2003-2006. MMWR 56 (2007) 170-172
15. Vescia S., Baumgärtner A.K., Jacobs V.R., et al. Management of venous port systems in oncology: a review of current evidence. Ann Oncol 19 (2008) 9-15
16. Torramadé J., Hernández J.L., Cienfuegos J.A., et al. The complications of central venous access systems: a study of 218 patients. Eur J Surg 159 (1993) 323-327
17. Groeger J.S., Lucas A.B., Thaler H.T., et al. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 119 (1993) 1168-1174
18. Vardy J., Engelhardt K., Cox K., et al. Long-term outcome of radiological-guided insertion of implanted central venous access port devices (CVAPD) of the delivery of chemotherapy in cancer patients: institutional experience and review of the literature. Br J Cancer 91 (2004) 1045-1049
19. Mirro J., Rao B.N., Stokes D.C., et al. A prospective study of Hickman/Broviac catheters and implantable ports in pediatric oncology patients. J Clin Oncol 7 (1989) 214-222
20. Kock H.-J., Pietsch M., Krause U., et al. Implantable vascular access system: experience in 1500 patients with totally implanted central venous port systems. World J Surg 22 (1998) 12-16
21. Adler A., Yaniv I., Steinberg R., et al. Infectious complications of implantable ports and Hickman catheters in pediatric hematology-oncology patients. J Hosp Infect 62 (2006) 358-365
22. Doran A.K., Ivy D.D., Barst R.J., Hill N., et al. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract 160 suppl (2008) 5-9
23. Lorch H., Zwaan M., Hagel C., et al. Central venous access ports placed by interventional radiologist: experience with 125 consecutive patients. Diagn Interv Radiol 12 (2006) 93-98
24. Cil B.E., Canyigit M., Peynircioglu B., et al. Subcutaneous venous port implantation in adult patients: a single centre experience. Cardiovasc Intervent Radiol 24 (2001) 180-184